Myelodysplastic Syndrome News

News

Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS

10/02/2024

Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.

Luspatercept provides a new...

10/02/2024

Oncology

News

Initial Low Dose Lenalidomide Over 2 Years Improves Treatment Response Among Non-Transfusion-Dependent Patients With Low-Risk MDS

09/19/2024

Amber Denham ;

An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...

An initial treatment of low...

09/19/2024

Oncology

News

FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia

06/21/2024

The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...

The FDA granted approval to...

06/21/2024

Oncology

News

Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS

03/05/2024

Amber Denham

According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.

According to a retrospective...

03/05/2024

Oncology

News

Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML

02/21/2024

Amber Denham ;

Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.

Oral decitabine cedazuridine...

02/21/2024

Oncology

News

Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse

02/09/2024

Amber Denham ;

Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...

Evaluating individualized...

02/09/2024

Oncology

News

Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes

01/31/2024

Amber Denham ;

Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.

Azacitidine demonstrated low...

01/31/2024

Oncology

News

Sabatolimab Plus Hypomethylating Agents as Frontline Therapy for Patients With Higher-Risk MDS

01/11/2024

Amber Denham ;

A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...

A phase 2 trial determined that...

01/11/2024

Oncology

Conference Coverage

Fedratinib Demonstrates Promising Efficacy in MDS/MPN and Chronic Neutrophilic Leukemia

12/09/2023

Janelle Bradley ;

Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.

Data from a phase 2 trial show...

12/09/2023

Oncology

Conference Coverage

Phase 3 IMerge Study Confirms Clinical Efficacy of Imetelstat in Lower-Risk MDS Across Risk Categories

12/09/2023

Janelle Bradley ;

Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.

Imetelstat improves red blood...

12/09/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology